SILARUS THERAPEUTICS
Silarus Therapeutics is developing therapeutics targeting erythroferrone for the treatment of iron deficiency and iron overload disorders. Erythroferrone is a recently-discovered hormone that regulates the iron supply for red blood cell production. Iron deficiency, also known as anemia, is a condition in which blood does not contain the normal amount of red blood cells or lacks the proper amount of hemoglobin. This, in turn, lowers the amount of oxygen-rich blood in circulation, causing shortness of breath, dizziness or headaches.
SILARUS THERAPEUTICS
Industry:
Health Care Medical Therapeutics
Founded:
2014-01-01
Address:
La Jolla, California, United States
Country:
United States
Total Employee:
1+
Status:
Active
Total Funding:
10 M USD
Similar Organizations
Disarm Therapeutics
Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Rainier Therapeutics
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.
Viking Therapeutics
Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.
Current Employees Featured
Founder
Investors List
GlaxoSmithKline
GlaxoSmithKline investment in Series A - Silarus Therapeutics
Avalon Ventures
Avalon Ventures investment in Series A - Silarus Therapeutics